Mukka Proteins Limited (MUKKA) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Mukka Proteins Limited ₹29.50, price ₹25.70, upside +14.8%, quality 26 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Mukka Proteins Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
31‑month range ₹18.49 – ₹54.22 · fair‑value band ₹21.49 – ₹38.10 · the ₹25.70 price screens below the ₹29.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Mukka Proteins in your weekly email
Every Wednesday you see whether Mukka Proteins is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mukka Proteins Limited manufactures and sells fish protein products in India. The company offers fish meal, oil, and soluble paste; and ento meal, oil, and soil. It also provides insect meal, oil, and compost; and humic acid.
Show more
Mukka Proteins Limited manufactures and sells fish protein products in India. The company offers fish meal, oil, and soluble paste; and ento meal, oil, and soil. It also provides insect meal, oil, and compost; and humic acid. The company's products are used for aqua feed, poultry feed, pet feed, EPADHA extraction, animal feed, soap manufacture, leather tanneries, and paint industries. It also exports its products to Bahrain, Bangladesh, Chile, Indonesia, Malaysia, Myanmar, the Philippines, China, Saudi Arabia, South Korea, Oman, Taiwan, and Vietnam. The company was formerly known as Mukka Sea Food Industries Limited and changed its name to Mukka Proteins Limited in August 2021. The company was founded in 1960 and is based in Mangalore, India.
Stock analysis
Mukka Proteins Limited (MUKKA) currently trades at ₹25.70, while our model-based Fair Value estimate is ₹29.50, implying the stock looks roughly 12.9% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹51.95 per share, and 11 of the 14 models we run sit above the ₹25.70 price.
Bear case: the Asset-Based group reads lowest at ₹11.15, and 3 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹21.49 (bear) to ₹38.10 (bull), the price of ₹25.70 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Mukka Proteins Limited reported revenue of ₹14.5B in FY2026 versus ₹7.7B in FY2022, a compound +17.3%/yr. Reported net income was ₹521M in FY2026, compounding +21.1%/yr from FY2022.
Key figures
Market cap ₹7.7B (≈ $79.8M) · P/E ratio 11.1 · P/S ratio 0.40 · EPS (TTM) ₹2.32 · Net margin 3.6% · Return on equity 11.6% · Return on assets (EBIT) 10.9% · Operating margin 8.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 3% fair-value upside, at 15%, MUKKA screens cheaper than that median.
Fair Value models
Bear ₹21.49Fair Value ₹29.50Bull ₹38.10
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹1.18 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+31.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+31.7%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 7%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 626 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside+14.8% · Above median
Profitability
Return on equity (TTM)11.6% · Above median
Return on assets4.5% · Above median
Net margin (TTM)3.6% · Below median
Operating margin (TTM)7.6% · Above median
Growth and dividend
Revenue growth−0.3% · Below median
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Mukka Proteins Limited (MUKKA) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹29.50 versus a price of ₹25.70, about +15% upside (undervalued).
What is the fair value of MUKKA?
Our model-based fair value for Mukka Proteins Limited is ₹29.50 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹25.70.
What is the quality score of MUKKA?
Mukka Proteins Limited has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mukka Proteins Limited (MUKKA)?
Our model-based price target is the fair value of ₹29.50 (as of Oct 2, 2026) from 14 valuation models. Cautious scenario ₹21.49, optimistic scenario ₹38.10. It is a calculation from audited fundamentals, not an analyst target.
What is the Mukka Proteins Limited stock forecast for 2026?
Our models put fair value at ₹29.50, about +15% upside versus a price of ₹25.70 (undervalued). Cautious scenario ₹21.49, optimistic scenario ₹38.10. The calculation is refreshed regularly with new filings.
What is the revenue of Mukka Proteins Limited (MUKKA)?
Mukka Proteins Limited reported trailing-twelve-month revenue of about ₹17.7B (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Mukka Proteins Limited (MUKKA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mukka Proteins Limited it is ₹29.50 per share (as of Oct 2, 2026), against a price of ₹25.70. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Mukka Proteins Limited stock overvalued or undervalued in 2026?
As of Oct 2, 2026, MUKKA trades below its calculated fair value: price ₹25.70, fair value ₹29.50, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MUKKA?
No. The price is what the market pays today (₹25.70); the fair value is what the company's own numbers justify (₹29.50). For Mukka Proteins Limited the two are ₹3.80 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mukka Proteins Limited worth?
The market values Mukka Proteins Limited at about ₹7.7B (market capitalisation, as of Oct 2, 2026). Per share that is ₹25.70; our models calculate a fair value of ₹29.50 per share.
What do the bullish and bearish scenarios say about MUKKA?
Our models span a range for Mukka Proteins Limited: cautious scenario ₹21.49, base ₹29.50, optimistic ₹38.10 per share (as of Oct 2, 2026, price ₹25.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MUKKA?
Mukka Proteins Limited trades at a price-to-earnings ratio of 11.1 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹29.50 is built from several models across several years. Other multiples: P/B 1.5, P/S 0.5, EV/EBITDA 6.5.
How solid is the balance sheet of Mukka Proteins Limited (MUKKA)?
Balance-sheet figures for Mukka Proteins Limited (as of Oct 2, 2026): return on equity 11.6%, debt of 0.06 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is MUKKA from its 52-week high?
Mukka Proteins Limited trades at ₹25.70, about 20% below its 52-week high of ₹32.17 and 39% above the low of ₹18.49 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹29.50 is for.
Which stocks are comparable to Mukka Proteins Limited?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mukka Proteins Limited stock attractive at the current price?
The data as of Oct 2, 2026: price ₹25.70, calculated fair value ₹29.50 (+15%), Quality Score 26/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MUKKA calculated?
We run Mukka Proteins Limited through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹29.50, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Mukka Proteins Limited currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mukka Proteins Limited (MUKKA)?
The closing price on Oct 1, 2026 was ₹25.70. Our model-based fair value is ₹29.50, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mukka Proteins Limited right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Mukka Proteins Limited
How large is the market capitalisation of Mukka Proteins Limited (MUKKA)?
The market capitalisation of Mukka Proteins Limited is ₹7.7B (≈ $79.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mukka Proteins Limited (MUKKA)?
The price-to-sales ratio of Mukka Proteins Limited is 0.40 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mukka Proteins Limited (MUKKA)?
Earnings per share at Mukka Proteins Limited are ₹2.32 (price ÷ EPS = P/E 11.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Mukka Proteins Limited (MUKKA)?
The net margin of Mukka Proteins Limited is 3.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mukka Proteins Limited (MUKKA)?
The return on equity (ROE) of Mukka Proteins Limited is 11.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mukka Proteins Limited (MUKKA)?
On an EBIT basis the return on assets of Mukka Proteins Limited is 10.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mukka Proteins Limited (MUKKA)?
The operating margin of Mukka Proteins Limited is 8.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mukka Proteins Limited (MUKKA)?
Revenue at Mukka Proteins Limited is growing +187% versus a year earlier (3y avg +7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mukka Proteins Limited (MUKKA)?
Earnings per share at Mukka Proteins Limited are growing +11.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Mukka Proteins Limited (MUKKA) generate?
The free cash flow of Mukka Proteins Limited is −₹3.0B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mukka Proteins Limited (MUKKA) carry?
The net debt of Mukka Proteins Limited is ₹7.2B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Mukka Proteins Limited in the live analysis
One click puts Mukka Proteins Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
